Form 4: Atea Pharmaceuticals Director Polly Murphy Reports Significant Equity Grants

Atea Pharmaceuticals, Inc. Director Polly A. Murphy reported the acquisition of common stock through RSU conversion and new grants of restricted stock units and stock options, aligning her interests with shareholders.

Summary

• Polly A. Murphy, a Director of Atea Pharmaceuticals, Inc. (AVIR), reported changes in her beneficial ownership of company securities.
• On June 20, 2025, Ms. Murphy acquired 29,600 shares of Common Stock upon the conversion of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• Following this transaction, Ms. Murphy directly beneficially owns 86,045 shares of Common Stock.
• Concurrently, Ms. Murphy was granted 29,600 new Restricted Stock Units (RSUs) at a price of $0.00 per unit.
• These new RSUs are set to vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date (June 20, 2025), subject to her continued service.
• Additionally, Ms. Murphy was granted 41,200 Stock Options (Right to Buy) at a price of $0.00 per option, with an exercise price of $3.25 per share.
• These stock options will vest and become exercisable in twelve substantially equal monthly installments following June 20, 2025, becoming fully vested on the first anniversary of the grant date, subject to her continued service.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Form 4) detailing insider equity transactions. It does not contain information that would typically indicate a positive or negative sentiment about the company's operational or financial performance, but rather reflects standard compensation practices.

Positives

• The grants of Restricted Stock Units and Stock Options to Director Polly A. Murphy align her financial interests with those of the company's shareholders, incentivizing long-term performance.
• The acquisition of common stock through RSU conversion indicates a vesting event, reflecting the director's continued service and commitment to the company.

Risks

• The vesting of both the Restricted Stock Units and Stock Options is contingent upon Polly A. Murphy's continued service to Atea Pharmaceuticals, Inc., meaning the benefits are not guaranteed if her service ceases before vesting dates.

Future Outlook

The Restricted Stock Units granted on June 20, 2025, are expected to vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date. The Stock Options granted on June 20, 2025, are expected to vest in twelve substantially equal monthly installments, becoming fully vested on the first anniversary of the grant date, both subject to continued service.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, common across publicly traded companies in the biotechnology and pharmaceutical sectors. It reflects standard practices for compensating directors with equity to align their interests with long-term company performance.

Related Party Transactions

• The reported transactions involve equity grants and conversions between Atea Pharmaceuticals, Inc. and its Director, Polly A. Murphy, which are considered related party transactions as part of director compensation.

Stakeholder Impact

• Shareholders: The equity grants to a director are intended to align management's interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: While not directly impacting all employees, the compensation structure for directors can set a precedent or reflect the company's overall approach to equity-based incentives.

Next Steps

• The Restricted Stock Units are expected to vest on the earlier of the next annual meeting of Atea Pharmaceuticals' stockholders or June 20, 2026 (first anniversary of grant date).
• The Stock Options will vest in twelve monthly installments following June 20, 2025, with full vesting expected by June 20, 2026.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, SEC Form 4, Insider Trading, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership, Corporate Governance